Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NantCell, Inc.
Age
16–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Part 1: Histologically or cytologically confirmed, locally advanced or metastatic, treatment-refractory solid tumors
Part 2: Histologically or cytologically confirmed, locally advanced or metastatic: NSCLC (squamous or non-squamous cell carcinoma; up to 2 prior treatment regimens), Colorectal Cancer (up to 2 prior treatment regimens), Pancreatic Cancer (up to 1 prior treatment regimen), Ovarian cancer (up to 2 prior treatment regimens), or Sarcoma (up to 2 prior treatment regimens), according to cohort availability
Eastern Cooperative Group (ECOG performance status of 0 or 1
Women or men ≥16 years of age
Adequate hematology, renal, hepatic, coagulation and glycemic function.
You may not be if
Presence of uncontrolled central nervous system (CNS) disease
Systemic chemotherapy, hormonal therapy, immunotherapy, experimental or approved anticancer proteins/antibodies therapy ≤28 days before enrollment.
Prior treatment with death receptor agonists (including but not limited to rhApo2L/TRAIL \[AMG951\], apomab, mapatumumab, lexatumumab, CS-1008)
Prior treatment with IGF receptor antagonists (including but not limited to CP-751, 871, MK0646, AVE1642 or IMC-A12)
Clareo Health | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
